Last updated: February 19, 2026
This report analyzes Canadian patent CA2928969, focusing on its asserted scope, detailed claims, and the surrounding patent landscape. The patent, assigned to Allergan, Inc., pertains to a pharmaceutical composition and its use for treating ocular conditions, specifically dry eye disease. The analysis identifies key patent families, potential infringement risks, and strategic considerations for stakeholders.
What is the Core Invention of CA2928969?
Patent CA2928969 protects a pharmaceutical composition comprising a cyclodextrin complex of cyclosporine and a method for treating dry eye disease. The composition aims to improve the delivery and efficacy of cyclosporine in the treatment of this condition.
The patent claims a composition that includes:
- Cyclosporine.
- A cyclodextrin.
- A pharmaceutically acceptable vehicle.
The invention's novelty and utility stem from the specific formulation of cyclosporine with cyclodextrin, which is designed to enhance its solubility and ocular penetration. This formulation is intended to provide a more effective treatment for dry eye disease, a chronic inflammatory condition affecting the ocular surface.
What are the Key Claims of CA2928969?
The patent's claims define the legal boundaries of the protected invention. CA2928969 has several independent and dependent claims covering the composition and its use.
Independent Claim 1 defines the pharmaceutical composition:
A pharmaceutical composition comprising:
(a) cyclosporine;
(b) a cyclodextrin; and
(c) a pharmaceutically acceptable vehicle.
Independent Claim 11 defines a method of treating dry eye disease:
A method of treating dry eye disease in a subject, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1.
Dependent Claims further refine these aspects, specifying parameters such as:
- The type of cyclodextrin (e.g., hydroxypropyl-β-cyclodextrin).
- The concentration of cyclosporine.
- The properties of the vehicle (e.g., a sterile aqueous solution or suspension).
- Specific dosages and administration frequencies.
These claims establish a broad protection for the cyclodextrin complex of cyclosporine when formulated for ophthalmic use and its application in dry eye treatment.
What is the Exclusivity Period for CA2928969?
Canadian patent law grants a term of 20 years from the filing date, subject to the payment of maintenance fees.
- Filing Date: April 23, 2015
- Issue Date: November 7, 2017
- Expiry Date: April 23, 2035
This expiry date indicates the period during which the patent holder can exclusively control the manufacturing, use, and sale of the patented invention in Canada. However, extensions may be available for pharmaceutical patents under specific circumstances, such as regulatory review delays. A comprehensive analysis of potential extensions for CA2928969 would require detailed examination of its regulatory history and any applicable legislation amendments.
Who Owns CA2928969?
The patent CA2928969 is assigned to Allergan, Inc. Allergan, now part of AbbVie, is a biopharmaceutical company with a significant portfolio in ophthalmology. This ownership suggests that the patented technology is likely linked to Allergan's commercial products in the dry eye market.
What is the Current Patent Landscape for Cyclosporine and Dry Eye Treatments in Canada?
The patent landscape surrounding cyclosporine for dry eye treatment is complex, with multiple patents covering various formulations, delivery systems, and therapeutic methods. Understanding this landscape is critical for assessing freedom to operate and identifying potential infringement.
Key Players and Technologies:
- Allergan/AbbVie: Holds CA2928969 and potentially other patents related to its cyclosporine ophthalmic emulsions. Restasis® (cyclosporine ophthalmic emulsion 0.05%) is a primary product associated with this patent family. Subsequent products or formulations may be covered by later-filed patents.
- Other Cyclosporine Formulations: Various companies have explored and patented different methods to formulate and deliver cyclosporine for ocular conditions. This includes different concentrations, excipients, and delivery devices.
- Novel Dry Eye Treatments: The landscape also includes patents on entirely different mechanisms of action for dry eye disease, such as anti-inflammatory agents, secretagogues, and artificial tears. These represent alternative therapeutic approaches that may not directly conflict with CA2928969 but contribute to the overall competitive environment.
Patent Filing Trends:
Analysis of patent filing data reveals a sustained interest in ocular drug delivery and dry eye therapies over the past two decades. While early filings focused on the active pharmaceutical ingredient (API) itself, more recent filings often target specific formulations, manufacturing processes, and methods of use to achieve narrower, more defensible patent protection.
Freedom to Operate Considerations:
Companies seeking to develop or market cyclosporine-based dry eye treatments in Canada must conduct thorough freedom to operate (FTO) analyses. This involves:
- Identifying Relevant Patents: Mapping all active patents covering cyclosporine formulations, compositions, and methods of treatment for dry eye disease.
- Claim Construction: Analyzing the scope of claims in relevant patents to determine if a proposed product or process would infringe.
- Validity Challenges: Assessing the potential invalidity of competitor patents based on prior art.
CA2928969, with its broad claims on a cyclodextrin complex of cyclosporine for dry eye treatment, represents a significant patent to navigate for any entity entering this space.
What are the Potential Infringement Risks Associated with CA2928969?
Infringement of CA2928969 can occur if a third party manufactures, uses, or sells a pharmaceutical composition or employs a method that falls within the scope of its claims without authorization.
Key Infringement Pathways:
- Direct Infringement of Composition Claims: Developing and marketing an ophthalmic formulation that contains cyclosporine, a cyclodextrin, and a pharmaceutically acceptable vehicle, where the formulation's characteristics align with the patent's claims. This is particularly relevant if the formulation uses a cyclodextrin to enhance cyclosporine delivery.
- Direct Infringement of Method Claims: Prescribing or administering a treatment regimen for dry eye disease that utilizes a composition meeting the description in Claim 1, where the administration is done without a license from the patent holder.
- Indirect Infringement: In cases where a third party supplies a component specifically designed for infringing a claim, or actively induces infringement.
Given Allergan's (AbbVie's) established presence in the dry eye market with cyclosporine products, CA2928969 is likely a critical piece of their intellectual property strategy. Competitors seeking to introduce similar formulations or treatments would face a substantial hurdle in navigating this patent.
What are the Strategic Implications for Stakeholders?
For Pharmaceutical Companies Developing Dry Eye Treatments:
- Design Around: Companies must meticulously design their products and processes to avoid infringing the claims of CA2928969 and other relevant patents. This may involve exploring alternative cyclosporine formulations (without cyclodextrins, or with different excipients/delivery systems) or entirely different therapeutic mechanisms for dry eye.
- Licensing: If a desired formulation or method is covered by CA2928969, obtaining a license from Allergan/AbbVie would be necessary. This involves negotiation and potentially significant royalty payments.
- Patent Challenge: Companies may consider challenging the validity of CA2928969 based on prior art or other legal grounds, though this is a high-risk, high-cost endeavor.
For Investors:
- Competitive Analysis: Understanding the patent portfolio of key players like Allergan/AbbVie is crucial for assessing competitive advantages and market exclusivity. The existence and expiry of patents like CA2928969 directly impact the investment thesis for companies operating in the dry eye therapeutic area.
- Pipeline Risk: For companies developing products that might compete with Allergan's cyclosporine-based therapies, the patent landscape represents a significant risk factor that can affect market entry timelines and potential profitability.
- Generic/Biosimilar Entry: The expiry of CA2928969 in 2035 will open opportunities for generic or biosimilar competition, provided no further patent term extensions are granted and no other blocking patents exist.
For Healthcare Providers and Patients:
- Treatment Options: The existence of strong patent protection can limit the availability of therapeutic options and potentially influence pricing. As patents expire, increased competition can lead to more affordable treatments.
- Innovation Incentive: Patents incentivize companies to invest in R&D for novel treatments by granting a period of market exclusivity. This ultimately can lead to improved therapies for patients.
Key Takeaways
Patent CA2928969, owned by Allergan, Inc. (AbbVie), protects a pharmaceutical composition involving a cyclodextrin complex of cyclosporine and its use in treating dry eye disease. The patent's independent claims cover the composition itself and the method of treating the condition. With a filing date of April 23, 2015, the patent is set to expire on April 23, 2035, though potential extensions should be monitored. The surrounding patent landscape is active, with numerous patents addressing various aspects of dry eye treatments. Stakeholders must conduct thorough freedom-to-operate analyses to avoid infringement, and consider licensing or challenging existing patents. For investors, this patent represents a key element of Allergan/AbbVie's market exclusivity in the dry eye sector.
Frequently Asked Questions
-
Does CA2928969 cover all forms of cyclosporine used for dry eye?
No, CA2928969 specifically covers compositions comprising cyclosporine in a cyclodextrin complex, along with a pharmaceutically acceptable vehicle, and their use in treating dry eye. Other formulations of cyclosporine not employing a cyclodextrin complex, or used for different indications, would not be directly covered by this patent's core claims.
-
Can a generic version of Allergan's cyclosporine dry eye product be launched before April 23, 2035?
A generic launch would depend on the expiration of all relevant patents covering the specific product, not solely CA2928969. If other blocking patents exist, or if CA2928969 receives patent term extension, the generic launch could be delayed. A comprehensive FTO analysis is required to determine this.
-
What is the significance of "cyclodextrin" in the patent claims?
The inclusion of cyclodextrin is a key element distinguishing the claimed invention. Cyclodextrins are known to enhance the solubility, stability, and bioavailability of various drugs, including cyclosporine. This specific formulation approach is central to the patent's scope.
-
Are there any other Allergan/AbbVie patents that could extend the exclusivity of their cyclosporine dry eye treatment beyond 2035?
It is common for pharmaceutical companies to file multiple patents covering different aspects of a drug, including formulation improvements, manufacturing processes, and new indications. A thorough review of Allergan/AbbVie's entire Canadian patent portfolio related to cyclosporine and dry eye is necessary to identify any such secondary patents or potential patent term extensions.
-
What are the main challenges in designing around CA2928969?
The primary challenge is to develop a cyclosporine-based dry eye treatment that does not incorporate a cyclodextrin complex as claimed in the patent, or to use a different method of treatment that falls outside the patent's scope. Alternative excipients or delivery systems that do not infringe on the cyclodextrin aspect are potential avenues, but these also require careful analysis to avoid infringing other existing patents.
Citations
[1] Allergan, Inc. (2017). Pharmaceutical composition and method of treatment. CA 2928969. Canadian Intellectual Property Office.
